US Patent

US12539283 — Epinephrine liquid formulations

Formulation · Assigned to Fresenius Kabi USA LLC · Expires 2045-01-17 · 19y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a stable pharmaceutical formulation of epinephrine or a pharmaceutically acceptable salt thereof, with specific ingredients and pH range.

USPTO Abstract

The invention provides a stable, pharmaceutical formulation comprising epinephrine or a pharmaceutically acceptable salt thereof. The formulation includes an organic acid, a tonicity agent, and water, has a pH of about 3.0 to about 3.6, and is substantially free of a conjugate base of the organic acid.

Drugs covered by this patent

Patent Metadata

Patent number
US12539283
Jurisdiction
US
Classification
Formulation
Expires
2045-01-17
Drug substance claim
No
Drug product claim
Yes
Assignee
Fresenius Kabi USA LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.